Discovery of new oxadiazolo pyridine derivatives as potent ghrelin O-acyltransferase inhibitors using molecular modeling techniques.
ADMET
DFT
Ghrelin O-acyltransferase
Molecular docking
Molecular dynamics simulation
Oxadiazolo pyridine
QSARINS
Journal
In silico pharmacology
ISSN: 2193-9616
Titre abrégé: In Silico Pharmacol
Pays: Germany
ID NLM: 101623954
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
02
2023
accepted:
04
10
2023
pmc-release:
09
11
2024
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Diabesity is a major global health concern, and ghrelin O-acyltransferase (GOAT) acts as an important target for the development of new inhibitors of this disease. The present work highlights a detailed QSAR study using QSARINS software, which provides an excellent model equation using descriptors. Here, the best model equation developed has two variables, namely MLFER_E and XlogP, with statistical parameters R METTL3-mediated HOTAIRM1 promotes vasculogenic mimicry in glioma via regulating IGFBP2 expression. METTL3 expression is high in glioma cells and tissues that stabilize and enhance HOTAIRM1 expression. This HOTAIRM1 then interacts with IGFBP2 which in turn promotes glioma cell malignancy and vasculogenic mimicry (VM) formation, thus providing a new direction for glioma therapy. The online version contains supplementary material available at 10.1007/s40203-023-00167-z.
Identifiants
pubmed: 37954893
doi: 10.1007/s40203-023-00167-z
pii: 167
pmc: PMC10632319
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare no conflict of interest.
Références
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6320-5
pubmed: 18443287
J Phys Chem B. 2016 Apr 21;120(15):3692-8
pubmed: 27031562
Cell Metab. 2018 Apr 3;27(4):786-804
pubmed: 29576534
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Chem Theory Comput. 2008 Feb;4(2):297-306
pubmed: 26620661
RSC Med Chem. 2020 Sep 4;11(10):1136-1144
pubmed: 33479618
J Chem Inf Model. 2012 Dec 21;52(12):3144-54
pubmed: 23146088
Physiol Rev. 2005 Apr;85(2):495-522
pubmed: 15788704
Biochemistry. 2015 Feb 3;54(4):1100-10
pubmed: 25562443
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10750-5
pubmed: 18669668
J Comput Chem. 2014 May 15;35(13):1036-44
pubmed: 24599647
Nephrol Dial Transplant. 2011 Jan;26(1):28-35
pubmed: 21045078
J Comput Chem. 2011 May;32(7):1466-74
pubmed: 21425294
Cell. 2008 Feb 8;132(3):387-96
pubmed: 18267071
Comput Biol Med. 2022 Nov;150:106209
pubmed: 36257276
Nature. 1999 Dec 9;402(6762):656-60
pubmed: 10604470
J Comput Chem. 2010 Mar;31(4):671-90
pubmed: 19575467
Adv Prev Med. 2019 May 2;2019:5173786
pubmed: 31186969
Mol Divers. 2023 Jun;27(3):1297-1308
pubmed: 35831728
Endocr J. 2011;58(8):707-10
pubmed: 21646729
J Phys Chem B. 2014 Jan 16;118(2):547-56
pubmed: 24341749
Methods Enzymol. 2012;514:205-28
pubmed: 22975055
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
J Pak Med Assoc. 2013 Apr;63(4):532-4
pubmed: 23905459
Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):619-24
pubmed: 24100676
J Recept Signal Transduct Res. 2020 Aug;40(4):313-323
pubmed: 32228125
Expert Opin Ther Pat. 2020 Aug;30(8):581-593
pubmed: 32564644
J Biomol Struct Dyn. 2023 Nov;41(19):9424-9436
pubmed: 36336960